Neuralink growing rapidly following successful human trial

Earlier this year Elon Musk’s Neuralink—a technology project that uses brain implants for a variety of purposes, including as a medical device—revealed it had successfully completed its first human trial. Now, it appears the company has greatly expanded its workforce and is backed by some serious funding. 

A new report from CB Insights found Neuralink has ramped up hiring, expanding its workforce by 120% over the last two years, including more than a 16% increase since that successful human trial.

Further, the company has received $680 million from investors to date, the report said.

That number likely rose after it was revealed that Neuralink’s technology works. In January, Musk revealed in a social media post on X, formerly Twitter, that a 29-year old paralyzed man had received a Neuralink brain implant, allowing him to interface with a computer. That first implant is now a true product, called Telepathy, is a small device implanted into the brain by a robotic surgeon.

Going forward, Telepathy implants could have a variety of use cases for patients, including allowing them to use artificial limbs.

Neuralink now employs 453 people, according to CB Insights. Founded in 2017, the company was given FDA approval for its first human trials in May 2023. Those trials began the following September and are ongoing.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.